A BH3 Mimetic for Killing Cancer Cells
- PMID: 27315468
- DOI: 10.1016/j.cell.2016.05.080
A BH3 Mimetic for Killing Cancer Cells
Abstract
Venetoclax is a BH3 mimetic approved for treating chronic lymphocytic leukemia. Cancer cells are resistant to apoptosis but "primed for death" by elevated BCL-2, which binds to pro-apoptotic proteins and holds them in check. Venetoclax releases this antagonism and is the first approved drug to target a protein-protein interaction.
Copyright © 2016. Published by Elsevier Inc.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources